$HROW

Shojaei Amir sold $450K of HROW

Shojaei Amir (CHIEF SCIENTIFIC OFFICER) sold 11,250 shares of HARROW, INC. (HROW) at $40.00 ($0.45M total) on 2026-08-14.

Original reporting
SEC EDGAR · Shojaei Amir
Published Aug 17, 2026, 9:47 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 17, 2026, 10:17 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$HROW
Neutral
medium confidence
Mentioned
$HROW
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HROWNeutralLow
01

Why it matters

The newest disclosed fact is the open-market sale of 11,250 shares for about $450,000, with holdings after the transaction reported as 0 shares.

02

Market read

Traders may note insider selling, but the disclosure does not include guidance, clinical, regulatory, or deal information.

03

What to watch

The filing states no pre-arranged 10b5-1 plan, but that alone does not establish intent or future trading restrictions.

Relevance 4/10Novelty 3/10Timing: filed after-hours on 2026-08-17, covering a sale dated 2026-08-14

Background

This is an SEC Form 4 insider transaction for Harrow, Inc. (HROW) by its Chief Scientific Officer.

Company-level read

Ticker impact

$HROWNeutralMedium confidence
Context

SEC Form 4 shows Chief Scientific Officer Shojaei Amir sold 11,250 shares of Harrow at $40.00 on 2026-08-14.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-driven and typically fades unless accompanied by other disclosures.

Evidence & confidence

Form 4 insider sales are common and, absent additional context like material adverse events or guidance changes, usually have limited predictive value for price.

Market effects

No clear sector read-through from a single insider sale disclosure.

None indicated.

None indicated.

Counterpoint

The sale could be unrelated to company outlook (tax, diversification, personal liquidity), so it may not signal bearish fundamentals.

Key entities

  • Harrow, Inc.

    Company whose insider transaction is disclosed on Form 4.

  • Shojaei Amir

    Chief Scientific Officer who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HROWMedAI 8/10

What's Going On With Harrow Stock Friday? - Harrow (NASDAQ:HROW)

Harrow Inc. (NASDAQ:HROW) reported positive results from a clinical study of its ocular anesthetic IHEEZO, showing significant pain reduction compared to a control. Analysts noted the findings support long-term growth and maintained an Outperform rating. HROW shares were down 1.33% at $41.50 on Friday.

$HROWMed

Harrow (HROW): Strong Product Momentum Meets A Steep H2 Revenue Target

Harrow Inc. (HROW) reported H1 2026 revenue of $115M, below expectations, but reaffirmed its full-year guidance of $350M-$365M. Key products IHEEZO, VEVYE, and TRIESENCE showed strong growth, but the company faces a steep H2 revenue target. Harrow also announced a pending deal for TYRVAYA, expected to add $30M in 2027 revenue. Adjusted EBITDA was negative $1.2M for the quarter, and the company has $83.9M in cash.

$HROWMed

Harrow Q2 Earnings Call Highlights

Harrow (NASDAQ:HROW) reported Q2 revenue of $15.6M for IHEEZO, with demand up to 65,477 units (+44% sequential, +34% YoY) but revenue lagging due to distributor sell-through of prior inventory. Management cited normalized channel inventory, ~25% higher net pricing effective July 1, gross margin 71%, and cash of $83.9M. Harrow also discussed BYOOVIZ launch, VEVYE PBM coverage, and a pending TYRVAYA acquisition.

$HROWMed

HARROW, INC. (HROW): Results of Operations and Financial Condition

HARROW, INC. (HROW) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Harrow Announces Second Quarter 2026 Financial Results Second Quarter 2026 and Selected Highlights: ● Quarterly revenue of $70.7 million, an increase of 60% sequentially, and 11% year over year ● Reiterated full-year 2026 financial guidance of $350 million to $365 mi